Biochemists open path to molecular 'chaperone' therapy for metabolic disease
Babies born with a faulty copy of a single gene that codes for one of several enzymes used in the cell's lysosomes -- recycling machines -- have lysosomal storage disorders of varying severity. The faulty gene means the enzymes fail to clean up used, toxic molecules or substrate. When these enzymes underperform or fail, patients can have serious metabolic problems. Credit: courtesy of Scott Garman, UMass Amherst
University of Massachusetts Amherst researchers, experts in revealing molecular structure by X-ray crystallography, have identified two new small "chaperone" molecules that may be useful in treating the inherited metabolic disorder known as Schindler/Kanzaki disease. This offers hope for developing the first ever drug treatment for this very rare disease.
Findings are reported in the current issue of Proceedings of the National Academy of Sciences. First author Nathaniel Clark conducted this work for his doctoral degree at UMass Amherst with his advisor, biochemist Scott Garman, plus others at UMass Amherst and at Oxford University, U.K. The work was supported by the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of General Medical Sciences (NIGMS).
Schindler/Kanzaki is one in a family of more than 50 very rare lysosomal storage diseases that together affect about 7,000 to 8,000 births per year, with no cure at present and few treatment options.
Babies born with it have a faulty copy of a single gene that codes for the alpha-N-acetylgalactosaminidase (alpha-NAGAL) enzyme, one of the cell's "recycling" machines that clean up used, toxic molecules, or substrate. When it works normally, alpha-NAGAL breaks down a sugar-containing substrate in the cell's recycling center, the lysosome. If alpha-NAGAL underperforms or fails, patients have neuromuscular problems such as seizures and muscle weakness. Garman says, "Some substrates are very toxic and children born with these diseases are really, really sick, many only living a short time."
The faulty gene causes its damage by misfolding proteins, yielding an unstable, poorly functioning alpha-NAGAL enzyme. One route to treat the disease is to stabilize alpha-NAGAL by using small molecules as so-called "pharmacological chaperones." The two molecules two Garman and colleagues identified and tested keep the alpha-NAGAL enzyme on track to proper folding.
In their paper, the UMass Amherst researchers show how these chaperones, sugar mimics (iminosugars) DGJ and DGJNAc, stabilize the defective alpha-NAGAL enzyme. Further, Clark, Garman and colleagues for the first time demonstrate by biochemical, crystallographic and cellular experiments exactly how the small molecule binds to the enzyme and provides that stability.
"People had hypothesized that this approach, using DGJNAc to treat Schindler disease, would work," Garman says. "Now we have shown for the first time that it does. These experiments show we can add DGJNAc to cells and increase the amount of the Schindler enzyme. As the culmination of Nat Clark's PhD thesis, it's a great achievement for him. We were the first to discover the enzyme's structure in 2009, and now we've discovered the small molecules that bind and stabilize that enzyme."
Their current paper describes how the biochemists extended their earlier crystallographic studies. They developed assays to measure how the small molecule chaperones bind to alpha-NAGAL and how they affect the enzymatic activity, the stability, and the cellular location of alpha-NAGAL.
The biochemists hope this work, which outlines how the chaperones could be used in treatment, may lead to their approval for compassionate use as an experimental drug. DGJ has already been found safe in humans and is now in Phase III clinical trials for Fabry disease, another lysosomal storage disorder. Thanks to this work it and DGJNAc might be useful in treating patients with Schindler disease.
In earlier studies and the current work, the UMass Amherst research team used their special expertise in X-ray crystallography to create three-dimensional images of all atoms in a protein to understand how it changes shape to carry out its metabolic mission. "We started working on these enzymes because very little was known about their structures," Garman says. "As basic researchers, we think we can make the most impact in just such cases, where few fundamentals are known. All this then provides ammunition to others to take what we find and move it forward. Principles we learn about Schindler disease can be applied to the whole family of lysosomal disorders."
Journal reference: Proceedings of the National Academy of Sciences
Provided by University of Massachusetts Amherst
- Biochemists develop promising new treatment direction for rare metabolic diseases Dec 22, 2011 | not rated yet | 0
- Biochemists Provide New Key for Treating Fabry Disease, a Rare Childhood Disorder Feb 02, 2010 | not rated yet | 0
- Einstein researchers discover important clue to the cause of Parkinson's disease Jan 02, 2008 | not rated yet | 0
- In lab, drug-on-the-cob fights rare disease Sep 18, 2012 | not rated yet | 0
- Calcium aids protein folding as therapy for enzymes in types of lysosomal storage diseases Feb 05, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
7 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
Medical research 1 hour ago | 5 / 5 (1) | 0 |
(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...
Medical research 2 hours ago | 5 / 5 (1) | 0 |
(Medical Xpress)—According to the World Health Organization, approximately 70 million couples experience infertility worldwide. Current data suggests that nearly one third of infertility disorders are due ...
Medical research 3 hours ago | 5 / 5 (1) | 0
Every day, their baby stopped breathing, his collapsed bronchus blocking the crucial flow of air to his lungs. April and Bryan Gionfriddo watched helplessly, just praying that somehow the dire predictions ...
Medical research 18 hours ago | 5 / 5 (3) | 0
The human gut is loaded with commensal bacteria – "good" microbes that, among other functions, help the body digest food. The gastrointestinal tract contains literally trillions of such cells, and yet the ...
Medical research 22 hours ago | 5 / 5 (3) | 0 |
A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have ...
20 minutes ago | not rated yet | 0 |
Nervous about that upcoming job interview? You might want to take steps to reduce your jitters, especially if you are a man.
6 minutes ago | not rated yet | 0
22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...
22 minutes ago | not rated yet | 0
A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...
30 minutes ago | not rated yet | 0
Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.
1 hour ago | 5 / 5 (1) | 0 |
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
2 hours ago | not rated yet | 0 |